1
|
Ramadan M, A M M Elshaier Y, Aly AA, Abdel-Aziz M, Fathy HM, Brown AB, Pridgen JR, Dalby KN, Kaoud TS. Development of 2'-aminospiro [pyrano[3,2-c]quinoline]-3'-carbonitrile derivatives as non-ATP competitive Src kinase inhibitors that suppress breast cancer cell migration and proliferation. Bioorg Chem 2021; 116:105344. [PMID: 34598088 DOI: 10.1016/j.bioorg.2021.105344] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2021] [Revised: 08/31/2021] [Accepted: 09/07/2021] [Indexed: 02/03/2023]
Abstract
Src kinase activity controls diverse cellular functions, including cell growth, migration, adhesion, and survival. It is de-regulated in several cancers, including breast cancer, where it is highly expressed and phosphorylated. Thus, targeting Src by a small molecule is a feasible strategy for managing different breast cancer types. Several Src kinase inhibitors are available, including the FDA-approved drug (dasatinib). However, they are primarily ATP-competitive inhibitors that have been reported to lack specificity towards Src. We have a long-time interest in discovering protein kinase inhibitors that are non-competitive for ATP. In this project, three groups of 2'-aminospiro[pyrano[3,2-c]quinoline]-3'-carbonitrile derivatives were designed and synthesized, hypothesizing that small molecules with a spiro scaffold appended to a pyrano[3,2-c]quinoline analog could act as non-ATP competitive Src kinase inhibitors. 3b, 3c, and 3d inhibited Src kinase activity with IC50s of 4.9, 5.9, and 0.9 μM, respectively. At the same time, they did not impact the MDM2/p53 interaction in HEK293 cells, which has been reported to be affected by some spirocyclic compounds. 25 µM of 3b, 3c, or 3d did not inhibit the kinase activity of ERK2, JNK1, or p38-alpha in an in-vitro kinase assay. Steady-state kinetic studies for the effect of 3d on the ability of recombinant Src to phosphorylate its substrate (Srctide) revealed a non-ATP competitive inhibition mechanism. 1.6 µM of 3d was enough to diminish Src, Fak, and paxillin phosphorylation in the breast cancer cell lines MDA-MB-231 and MCF7. In the NCI screening, 3d induced broad tumor cytotoxicity for the NCI-60 cell lines, including all the breast cancer cell lines. The potency of 3b, 3c, and 3d to inhibit migration, proliferation, and colony formation of MDA-MB-231 and proliferation of MCF7 cells correlates with their potency to suppress Src kinase activity in the same cell line. Noticeably, the cell growth suppression and apoptosis induction in the tested cell lines can be attributed to the ability of the new derivatives to suppress the ERK and Akt survival pathways downstream of Src.
Collapse
|
2
|
Guéguinou M, Felix R, Marionneau-Lambot S, Oullier T, Penna A, Kouba S, Gambade A, Fourbon Y, Ternant D, Arnoult C, Simon G, Bouchet AM, Chantôme A, Harnois T, Haelters JP, Jaffrès PA, Weber G, Bougnoux P, Carreaux F, Mignen O, Vandier C, Potier-Cartereau M. Synthetic alkyl-ether-lipid promotes TRPV2 channel trafficking trough PI3K/Akt-girdin axis in cancer cells and increases mammary tumour volume. Cell Calcium 2021; 97:102435. [PMID: 34167050 DOI: 10.1016/j.ceca.2021.102435] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Revised: 06/09/2021] [Accepted: 06/10/2021] [Indexed: 12/27/2022]
Abstract
The Transient Receptor Potential Vanilloid type 2 (TRPV2) channel is highly selective for Ca2+ and can be activated by lipids, such as LysoPhosphatidylCholine (LPC). LPC analogues, such as the synthetic alkyl-ether-lipid edelfosine or the endogenous alkyl-ether-lipid Platelet Activating Factor (PAF), modulates ion channels in cancer cells. This opens the way to develop alkyl-ether-lipids for the modulation of TRPV2 in cancer. Here, we investigated the role of 2-Acetamido-2-Deoxy-l-O-Hexadecyl-rac-Glycero-3-PhosphatidylCholine (AD-HGPC), a new alkyl-ether-lipid (LPC analogue), on TRPV2 trafficking and its impact on Ca2+ -dependent cell migration. The effect of AD-HGPC on the TRPV2 channel and tumour process was further investigated using calcium imaging and an in vivo mouse model. Using molecular and pharmacological approaches, we dissected the mechanism implicated in alkyl-ether-lipids sensitive TRPV2 trafficking. We found that TRPV2 promotes constitutive Ca2+ entry, leading to migration of highly metastatic breast cancer cell lines through the PI3K/Akt-Girdin axis. AD-HGPC addresses the functional TRPV2 channel in the plasma membrane through Golgi stimulation and PI3K/Akt/Rac-dependent cytoskeletal reorganization, leading to constitutive Ca2+ entry and breast cancer cell migration (without affecting the development of metastasis), in a mouse model. We describe, for the first time, the biological role of a new alkyl-ether-lipid on TRPV2 channel trafficking in breast cancer cells and highlight the potential modulation of TRPV2 by alkyl-ether-lipids as a novel avenue for research in the treatment of metastatic cancer.
Collapse
Affiliation(s)
- Maxime Guéguinou
- Inserm UMR 1069, Nutrition Croissance Cancer, Faculté de Médecine, Université de Tours, F-37032, France; PATCH Team, EA 7501 GICC, Faculté de Médecine, Université de Tours, F-37032, France
| | - Romain Felix
- Inserm UMR 1069, Nutrition Croissance Cancer, Faculté de Médecine, Université de Tours, F-37032, France
| | | | - Thibauld Oullier
- Inserm UMR 1235 TENS, Faculté de Médecine, Université de Nantes, F-44035, France
| | - Aubin Penna
- STIM Team, ERL CNRS 7349, UFR SFA Pole Biologie Santé, Université de Poitiers, F-86073, France
| | - Sana Kouba
- Inserm UMR 1069, Nutrition Croissance Cancer, Faculté de Médecine, Université de Tours, F-37032, France
| | - Audrey Gambade
- Inserm UMR 1069, Nutrition Croissance Cancer, Faculté de Médecine, Université de Tours, F-37032, France
| | - Yann Fourbon
- Inserm UMR 1069, Nutrition Croissance Cancer, Faculté de Médecine, Université de Tours, F-37032, France
| | - David Ternant
- PATCH Team, EA 7501 GICC, Faculté de Médecine, Université de Tours, F-37032, France
| | - Christophe Arnoult
- PATCH Team, EA 7501 GICC, Faculté de Médecine, Université de Tours, F-37032, France
| | - Gaëlle Simon
- Univ. Brest, CNRS, CEMCA UMR 6521, 6 Avenue Victor Le Gorgeu, Brest, F-29238, France
| | - Ana Maria Bouchet
- Inserm UMR 1069, Nutrition Croissance Cancer, Faculté de Médecine, Université de Tours, F-37032, France
| | - Aurélie Chantôme
- Inserm UMR 1069, Nutrition Croissance Cancer, Faculté de Médecine, Université de Tours, F-37032, France
| | - Thomas Harnois
- STIM Team, ERL CNRS 7349, UFR SFA Pole Biologie Santé, Université de Poitiers, F-86073, France
| | - Jean-Pierre Haelters
- Univ. Brest, CNRS, CEMCA UMR 6521, 6 Avenue Victor Le Gorgeu, Brest, F-29238, France
| | - Paul-Alain Jaffrès
- Univ. Brest, CNRS, CEMCA UMR 6521, 6 Avenue Victor Le Gorgeu, Brest, F-29238, France
| | - Gunther Weber
- Inserm UMR 1069, Nutrition Croissance Cancer, Faculté de Médecine, Université de Tours, F-37032, France
| | - Philippe Bougnoux
- Inserm UMR 1069, Nutrition Croissance Cancer, Faculté de Médecine, Université de Tours, F-37032, France
| | - François Carreaux
- UMR CNRS 6226, Institut des Sciences Chimiques de Rennes, Université de Rennes, F-35700, France
| | - Olivier Mignen
- Inserm UMR 1227 Immunothérapies et Pathologies Lymphocytaires B, CHU Morvan, Université de Bretagne Occidentale, Brest, F-29609, France
| | - Christophe Vandier
- Inserm UMR 1069, Nutrition Croissance Cancer, Faculté de Médecine, Université de Tours, F-37032, France
| | - Marie Potier-Cartereau
- Inserm UMR 1069, Nutrition Croissance Cancer, Faculté de Médecine, Université de Tours, F-37032, France.
| |
Collapse
|
3
|
Nguyen KTP, Druhan LJ, Avalos BR, Zhai L, Rauova L, Nesmelova IV, Dréau D. CXCL12-CXCL4 heterodimerization prevents CXCL12-driven breast cancer cell migration. Cell Signal 2019; 66:109488. [PMID: 31785332 DOI: 10.1016/j.cellsig.2019.109488] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2019] [Revised: 11/24/2019] [Accepted: 11/26/2019] [Indexed: 02/07/2023]
Abstract
Despite improvements in cancer early detection and treatment, metastatic breast cancer remains deadly. Current therapeutic approaches have very limited efficacy in patients with triple negative breast cancer. Among the many mechanisms associated that contribute to cancer progression, signaling through the CXCL12-CXCR4 is an essential step in cancer cell migration. We previously demonstrated the formation of CXCL12-CXCL4 heterodimers (Carlson et al., 2013). Here, we investigated whether CXCL12-CXCL4 heterodimers alter tumor cell migration. CXCL12 alone dose-dependently promoted the MDA-MB 231 cell migration (p < .05), which could be prevented by blocking the CXCR4 receptor. The addition of CXCL4 inhibited the CXCL12-induced cell migration (p < .05). Using NMR spectroscopy, we identified the CXCL4-CXCL12 binding interface. Moreover, we generated a CXCL4-derived peptide homolog of the binding interface that mimicked the activity of native CXCL4 protein. These results confirm the formation of CXCL12-CXCL4 heterodimers and their inhibitory effects on the migration of breast tumors cells. These findings suggest that specific peptides mimicking heterodimerization of CXCL12 might prevent breast cancer cell migration.
Collapse
Affiliation(s)
- Khanh T P Nguyen
- Department of Biological Sciences, UNC Charlotte, Charlotte, NC, United States of America
| | - Lawrence J Druhan
- Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, United States of America; Center for Biomedical Engineering and Science, UNC Charlotte, Charlotte, NC, United States of America
| | - Belinda R Avalos
- Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, United States of America; Center for Biomedical Engineering and Science, UNC Charlotte, Charlotte, NC, United States of America
| | - Li Zhai
- Department of Pediatrics, The Children's Hospital of Philadelphia, PA, United States of America
| | - Lubica Rauova
- Department of Pediatrics, The Children's Hospital of Philadelphia, PA, United States of America; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America
| | - Irina V Nesmelova
- Center for Biomedical Engineering and Science, UNC Charlotte, Charlotte, NC, United States of America; Department of Physics and Optical Science, UNC Charlotte, Charlotte, NC, United States of America
| | - Didier Dréau
- Department of Biological Sciences, UNC Charlotte, Charlotte, NC, United States of America; Center for Biomedical Engineering and Science, UNC Charlotte, Charlotte, NC, United States of America.
| |
Collapse
|
4
|
Flamini MI, Uzair ID, Pennacchio GE, Neira FJ, Mondaca JM, Cuello-Carrión FD, Jahn GA, Simoncini T, Sanchez AM. Thyroid Hormone Controls Breast Cancer Cell Movement via Integrin αV/β3/SRC/FAK/PI3-Kinases. Discov Oncol 2017; 8:16-27. [PMID: 28050799 DOI: 10.1007/s12672-016-0280-3] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2016] [Accepted: 12/20/2016] [Indexed: 11/26/2022] Open
Abstract
Thyroid hormones (TH) play a fundamental role in diverse processes, including cellular movement. Cell migration requires the integration of events that induce changes in cell structure towards the direction of migration. These actions are driven by actin remodeling and stabilized by the development of adhesion sites to extracellular matrix via transmembrane receptors linked to the actin cytoskeleton. Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that promotes cell migration and invasion through the control of focal adhesion turnover. In this work, we demonstrate that the thyroid hormone triiodothyronine (T3) regulates actin remodeling and cell movement in breast cancer T-47D cells through the recruitment of FAK. T3 controls FAK phosphorylation and translocation at sites where focal adhesion complexes are assembled. This process is triggered via rapid signaling to integrin αV/β3, Src, phosphatidylinositol 3-OH kinase (PI3K), and FAK. In addition, we established a cellular model with different concentration of T3 levels: normal, absence, and excess in T-47D breast cancer cells. We found that the expression of Src, FAK, and PI3K remained at normal levels in the excess of T3 model, while it was significantly reduced in the absence model. In conclusion, these results suggest a novel role for T3 as an important modulator of cell migration, providing a starting point for the development of new therapeutic strategies for breast cancer treatment.
Collapse
Affiliation(s)
- Marina Inés Flamini
- Laboratorio de Biología Tumoral. Instituto de Medicina y Biología Experimental de Cuyo, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Mendoza, Argentina
| | - Ivonne Denise Uzair
- Laboratorio de Transducción de Señales y Movimiento Celular. Instituto de Medicina y Biología Experimental de Cuyo (IMBECU), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Av. Ruiz Leal s/n. Parque Gral. San Martin CC855, 5500, Mendoza, Argentina
| | - Gisela Erika Pennacchio
- Laboratorio de Reproducción y Lactancia. Instituto de Medicina y Biología Experimental de Cuyo, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Mendoza, Argentina
| | - Flavia Judith Neira
- Laboratorio de Transducción de Señales y Movimiento Celular. Instituto de Medicina y Biología Experimental de Cuyo (IMBECU), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Av. Ruiz Leal s/n. Parque Gral. San Martin CC855, 5500, Mendoza, Argentina
| | - Joselina Magali Mondaca
- Laboratorio de Transducción de Señales y Movimiento Celular. Instituto de Medicina y Biología Experimental de Cuyo (IMBECU), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Av. Ruiz Leal s/n. Parque Gral. San Martin CC855, 5500, Mendoza, Argentina
| | - Fernando Dario Cuello-Carrión
- Laboratorio de Oncología. Instituto de Medicina y Biología Experimental de Cuyo, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Mendoza, Argentina
| | - Graciela Alma Jahn
- Laboratorio de Reproducción y Lactancia. Instituto de Medicina y Biología Experimental de Cuyo, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Mendoza, Argentina
| | - Tommaso Simoncini
- Molecular and Cellular Gynecological Endocrinology Laboratory (MCGEL), Department of Clinical and Experimental Medicine, University of Pisa, 56100, Pisa, Italy
| | - Angel Matías Sanchez
- Laboratorio de Transducción de Señales y Movimiento Celular. Instituto de Medicina y Biología Experimental de Cuyo (IMBECU), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Av. Ruiz Leal s/n. Parque Gral. San Martin CC855, 5500, Mendoza, Argentina.
| |
Collapse
|
5
|
Li NS, Zou JR, Lin H, Ke R, He XL, Xiao L, Huang D, Luo L, Lv N, Luo Z. LKB1/AMPK inhibits TGF-β1 production and the TGF-β signaling pathway in breast cancer cells. Tumour Biol 2015; 37:8249-58. [PMID: 26718214 PMCID: PMC4875963 DOI: 10.1007/s13277-015-4639-9] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2015] [Accepted: 12/10/2015] [Indexed: 12/30/2022] Open
Abstract
Adenosine monophosphate-activated protein kinase (AMPK) acts as a fuel gauge that maintains energy homeostasis in both normal and cancerous cells, and has emerged as a tumor suppressor. The present study aims to delineate the functional relationship between AMPK and transforming growth factor beta (TGF-β). Our results showed that expression of liver kinase B1 (LKB1), an upstream kinase of AMPK, impeded TGF-β-induced Smad phosphorylation and their transcriptional activity in breast cancer cells, whereas knockdown of LKB1 or AMPKα1 subunit by short hairpin RNA (shRNA) enhanced the effect of TGF-β. Furthermore, AMPK activation reduced the promoter activity of TGF-β1. In accordance, type 2 diabetic patients taking metformin displayed a trend of reduction of serum TGF-β1, as compared with those without metformin. A significant reduction of serum TGF-β1 was found in mice after treatment with metformin. These results suggest that AMPK inhibits the transcription of TGF-β1, leading to reduction of its concentration in serum. Finally, metformin suppressed epithelial-to-mesenchymal transition of mammary epithelial cells. Taken together, our study demonstrates that AMPK exerts multiple actions on TGF-β signaling and supports that AMPK can serve as a therapeutic drug target for breast cancer.
Collapse
Affiliation(s)
- Nian-Shuang Li
- Research Institute of Digestive Diseases and Department of Gastroenterology, The First Affiliated Hospital, Nanchang University, Nanchang, Jiangxi, China
- Graduate Program of Basic Medical Sciences, School of Basic Medical Sciences, Nanchang University, Nanchang, Jiangxi, China
| | - Jun-Rong Zou
- Research Institute of Digestive Diseases and Department of Gastroenterology, The First Affiliated Hospital, Nanchang University, Nanchang, Jiangxi, China
| | - Hui Lin
- Graduate Program of Basic Medical Sciences, School of Basic Medical Sciences, Nanchang University, Nanchang, Jiangxi, China
- Department of Biochemistry, Boston University School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA
| | - Rong Ke
- Graduate Program of Basic Medical Sciences, School of Basic Medical Sciences, Nanchang University, Nanchang, Jiangxi, China
| | - Xiao-Ling He
- Graduate Program of Basic Medical Sciences, School of Basic Medical Sciences, Nanchang University, Nanchang, Jiangxi, China
| | - Lu Xiao
- Graduate Program of Basic Medical Sciences, School of Basic Medical Sciences, Nanchang University, Nanchang, Jiangxi, China
| | - Deqiang Huang
- Research Institute of Digestive Diseases and Department of Gastroenterology, The First Affiliated Hospital, Nanchang University, Nanchang, Jiangxi, China
| | - Lingyu Luo
- Research Institute of Digestive Diseases and Department of Gastroenterology, The First Affiliated Hospital, Nanchang University, Nanchang, Jiangxi, China
| | - Nonghua Lv
- Research Institute of Digestive Diseases and Department of Gastroenterology, The First Affiliated Hospital, Nanchang University, Nanchang, Jiangxi, China.
| | - Zhijun Luo
- Graduate Program of Basic Medical Sciences, School of Basic Medical Sciences, Nanchang University, Nanchang, Jiangxi, China.
- Department of Biochemistry, Boston University School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA.
| |
Collapse
|